Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiary, Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory, received the Chinese drug administration's approval to conduct clinical trials on the Yupingfeng tea bag, according to a Shanghai Stock Exchange filing on Wednesday.
The product will be tested as a treatment for Hashimoto's thyroiditis, subclinical hypothyroidism and clinical hypothyroidism patients who exhibit symptoms of spleen and lung Qi deficiency after LT4 treatment, the pharmaceutical company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。